Omnitrope
Growth Hormone Deficiency
University Hospital, ToulousePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Growth Hormone Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Genotropin University of Calgary | Phase 4 | BBB |
Tesamorelin Columbia University | Phase 4 | B |
Growth Hormone Releasing Hormone 1-44 Massachusetts General Hospital | Phase 2 | B |
ADVICOR COMPONENT NIACIN Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1/2 | CCC |
Recombinant Gh Saizen Federico II University | Phase 3 | NR |
Same molecule, other indications
Omnitrope is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →